Urinary Concentration After Salmeterol
Urinary Concentration After Salmeterol in Well-trained Men and Females
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Morten Hostrup, PhD
- Phone Number: +4535321595
- Email: mhostrup@nexs.ku.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2100
- Recruiting
- August Krogh Building
-
Contact:
- Morten Hostrup, PhD
- Phone Number: +4535321595
- Email: mhostrup@nexs.ku.dk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Inclusion Criteria:
- Age 18-40
- Physically active >5 hours a week
- Maximum oxygen uptake classified as high or very high
Exclusion Criteria:
- Active smoker currently or within the past 5 years
- Regular intake of medication deemed by the responsible study physician to affect the test parameters (hormonal contraception is accepted for women)
- Chronic or acute illness deemed by the responsible study physician to affect the test parameters
- Deviation from the study protocol
- Lean mass index >21 kg/m²
- Pregnancy
- Smoker
- Blood donation during the past 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Normal conditions
Urine samples collected after various performance tests in normal conditions
|
Participants are administered salmeterol, after which they perform various performance tests in normal conditions.
Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
|
|
Experimental: Heated conditions
Urine samples collected after various performance tests in heated conditions
|
Participants are administered salmeterol, after which they perform various performance tests in heated conditions.
Following the administration of salmeterol, urine samples are collected over the next 24 hours at intervals of 0.5, 1, 2, 4, 8, and 24 hours after administration.
|
|
Other: Salmeterol inhalation and urine samples
Participants are administered daily salmeterol inhalation from an MDI device and are required to collect spot urine samples at home.
|
After the experimental day under normal conditions, all participants are administered 200 µg of salmeterol daily (8 puffs from the MDI device) during a 6-day intervention period.
Two hours after inhalation, the participants collect spot urine samples at home
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Urine concentration
Time Frame: Through study completion, an average on 1 week
|
Difference in urine concentration with salmeterol administered before performance tests in different conditions
|
Through study completion, an average on 1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Agents
- Adrenergic Agonists
- Adrenergic Agents
- Respiratory System Agents
- Anti-Asthmatic Agents
- Bronchodilator Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Salmeterol Xinafoate
Other Study ID Numbers
Other Study ID Numbers
- SALM_urine
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.